“[Tarceva] erlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL.” [1]
Patients receiving Tarceva had significantly longer median time to deterioration of pain, cough, and dyspnea. [1]
Proven to significantly improve quality of life [1]
- All predefined primary analyses demonstrated statistically and clinically relevant benefits in favor of patients receiving Tarceva. [1]
- In addition, secondary analyses showed that significantly more patients receiving Tarceva had improved global QOL and improvements in most functional domains. [1]
| Secondary endpoints were significantly improved with Tarceva treatment*†1 | Global QOL (P<0.0001) Physical functioning (P=0.01) Emotional functioning (P=0.01) Cognitive functioning (P=0.02) |
†Improvements indicate a 10-point or greater increase from baseline (scale of 0 to 100).
| Tarceva demonstrated significant symptom benefits by prolonging time to progression of symptoms that affect quality of life. [2] |
